Tag Archives: BristolCelgene

Activist Starboard steps up revolt on Bristol-Celgene merger—and BMS strikes back

First came the news that activist investor Starboard Value had bought up shares of Bristol-Myers Squibb with the intention of scuttling its planned $ 74 billion buyout of Celgene. Then, last week, BMS’ largest institutional shareholder, Wellington Management, spoke out against the deal, prompting Starboard CEO Jeffrey Smith to dash off a letter to BMS… Read More »